26 October 2011
Ellex Expands Position In Retinal Laser Market With New Photocoagulator Technology
Ellex Medical Lasers Limited, a manufacturer and distributor of ophthalmic technology, will launch a new photocoagulator laser platform for the treatment of retinal disease, branded as Integre Pro™, at the 2011 annual meeting of the American Academy of Ophthalmology (AAO).
The Integre Pro™ is the first photocoagulator to offer customized configuration of yellow, red and green wavelengths in an all-in-one laser/slit lamp design. This advanced laser platform allows ophthalmologists to choose from yellow-red, green-red, yellow or green wavelength configurations in order to best meet their clinical requirements – maximizing treatment flexibility and ensuring effective patient results.
Designed for consistent and repeatable treatment performance, the Integre Pro’s fully integrated laser/ slit lamp design ensures more stable and consistent energy delivery – and offers the added benefit of patient comfort and ease of operation.
“The Integre Pro starts by improving the physician’s vision”, commented Tom Spurling, Ellex CEO. “By integrating the treatment laser in the diagnostic slit lamp, we have eliminated the need for external mirrors or filters which can distort the physician’s view of the retina.”
Unlike other photocoagulator and multi-color laser systems, which require an external dichroic or fixed mirror in order to connect the laser to the slit lamp, the Integre Pro™ integrates the laser delivery optics inside the slit lamp to ensure that the laser beam is perfectly coaxial with the physician’s line of vision – providing a high-resolution image with optimum illumination of the fundus.
“There is simply no better system for the diagnosis and treatment of retinal disease,” said Mr Spurling.
Featuring a 10-degree stereoscopic angle, the system’s purpose-built slit lamp provides better depth perception and a wider peripheral view. In addition, the system’s True Spot™ optical system offers a uniform, sharp-edged top-hat beam on the retina with the added benefit of low power density at the cornea.
The Integre Pro’s red-yellow and red-green configurations deliver the full treatment spectrum of traditional multi-color lasers – and all at the touch of a button. Physicians are able to switch easily between wavelengths for seamless retinal treatments, allowing them to perform multiple procedures in one setting.
“With the Integre Pro, physicians can target localized pathologies with short laser shots, homogeneously distribute the laser energy over a large area for controlled applications in single shot mode, or quickly and efficiently apply the laser energy in repeat mode – all without disturbing their view of the treatment area,” said Mr. Spurling.
With the introduction of the Integre Pro™, Ellex will look to secure a larger share of the retinal laser market. Increases in life expectancy rates and changes in lifestyle and diet continue to contribute to an increased incidence of retinal eye disease – offering significant growth potential for the Integre Pro™.
“Historically, our focus has been on the YAG photodisruptor market for the treatment of secondary cataract. Whilst we have achieved significant success in this area – capturing a market leadership position – there is now an opportunity for us to target the larger, and more profitable, retinal laser market,” said Mr. Spurling.
Ellex Medical Lasers Limited (ASX:ELX) is a global leader in the design and manufacture of ophthalmic laser and ultrasound systems Ophthalmic Ultrasound used by ophthalmologists to diagnose and treat eye disease. With more than 15,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan, Germany and Australia, and a network of distribution partners in more than 100 countries. In recent years, Ellex has diversified its product range beyond lasers and ultrasound equipment to include distribution of a number of complementary third-party ophthalmic products.